Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed EBITDA Margin for 8 consecutive years, with 1479.45% as the latest value for Q1 2026.

  • Quarterly EBITDA Margin fell 113878.0% to 1479.45% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 1081.78% through Feb 2026, down 71641.0% year-over-year, with the annual reading at 340.16% for FY2025, 5036.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 1479.45% at Nurix Therapeutics, down from 1157.65% in the prior quarter.
  • The five-year high for EBITDA Margin was 87.25% in Q2 2023, with the low at 1479.45% in Q1 2026.
  • Average EBITDA Margin over 5 years is 479.23%, with a median of 370.28% recorded in 2022.
  • The sharpest move saw EBITDA Margin surged 41877bps in 2023, then plummeted -113878bps in 2026.
  • Over 5 years, EBITDA Margin stood at 717.82% in 2022, then soared by 58bps to 299.06% in 2023, then dropped by -8bps to 323.29% in 2024, then tumbled by -258bps to 1157.65% in 2025, then decreased by -28bps to 1479.45% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 1479.45%, 1157.65%, and 322.15% for Q1 2026, Q3 2025, and Q2 2025 respectively.